Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2011-04, Vol.67 (4), p.967-969 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 969 |
|---|---|
| container_issue | 4 |
| container_start_page | 967 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 67 |
| creator | Helbig, Grzegorz Moskwa, Andrzej Hus, Marek Piszcz, Jarosław Swiderska, Alina Urbanowicz, Alina Całbecka, Małgorzata Seferyńska, Ilona Raźny, Małgorzata Rodzaj, Marek Żuk, Ewa Kyrcz-Krzemień, Sławomira |
| description | |
| doi_str_mv | 10.1007/s00280-011-1582-3 |
| format | Article |
| fullrecord | <record><control><sourceid>hal_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3064899</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_HAL_hal_00671228v1</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-c97aa663420e20725cb6eb972f30a807e380f727d4cd0f42b2e7ed3dc48c690b3</originalsourceid><addsrcrecordid>eNp9kc9O3DAQxq2KqmyhD9BL5SsHt-M_GycXJAQsIK1UVJWz5TgTYpqNV3Z2ERIvxYv0mepVCqIcerI8833fePwj5DOHrxxAf0sAogQGnDM-LwWT78iMKykYlErukRlIpdhcg9onH1O6AwDFpfxA9gWXQldSzMjj2SbaukcaceVT8mGgth0x0jGiHVc4jPTejx3dYnygfbinTUiYaGipX9nRD76mbYh0cXXNl5xdn10sfvx-YuuQ_Oi3SF0Xw-AdxVwYwrrzfb70uPll8zh7SN63tk_46e95QG4W5z9PL9ny-8XV6cmSOaXnI3OVtrYopBKAArSYu7rAutKilWBL0ChLaLXQjXINtErUAjU2snGqdEUFtTwgx1PuelOvsHF5q2h7s455h_hggvXm387gO3MbtkZCocqqygFHU0D3xnZ5sjS7GkChuRDllmctn7QuhpQiti8GDmaHzUzYTMZmdtiMzJ4vrx_44njmlAViEqTcGm4xmruwiUP-tP-k_gE1K6WA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Helbig, Grzegorz ; Moskwa, Andrzej ; Hus, Marek ; Piszcz, Jarosław ; Swiderska, Alina ; Urbanowicz, Alina ; Całbecka, Małgorzata ; Seferyńska, Ilona ; Raźny, Małgorzata ; Rodzaj, Marek ; Żuk, Ewa ; Kyrcz-Krzemień, Sławomira</creator><creatorcontrib>Helbig, Grzegorz ; Moskwa, Andrzej ; Hus, Marek ; Piszcz, Jarosław ; Swiderska, Alina ; Urbanowicz, Alina ; Całbecka, Małgorzata ; Seferyńska, Ilona ; Raźny, Małgorzata ; Rodzaj, Marek ; Żuk, Ewa ; Kyrcz-Krzemień, Sławomira</creatorcontrib><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-011-1582-3</identifier><identifier>PMID: 21327932</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - pharmacokinetics ; Antineoplastic Agents - therapeutic use ; Benzamides ; Cancer ; Cancer Research ; Chronic Disease ; Dose-Response Relationship, Drug ; Female ; Follow-Up Studies ; Humans ; Hypereosinophilic Syndrome - drug therapy ; Hypereosinophilic Syndrome - pathology ; Imatinib Mesylate ; Letter to the Editor ; Life Sciences ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; mRNA Cleavage and Polyadenylation Factors - genetics ; Oncogene Proteins, Fusion - genetics ; Oncology ; Pharmacology/Toxicology ; Piperazines - administration & dosage ; Piperazines - pharmacokinetics ; Piperazines - therapeutic use ; Pyrimidines - administration & dosage ; Pyrimidines - pharmacokinetics ; Pyrimidines - therapeutic use ; Receptor, Platelet-Derived Growth Factor alpha - genetics ; Remission Induction - methods ; Retrospective Studies ; Splenomegaly - etiology ; Time Factors ; Young Adult</subject><ispartof>Cancer chemotherapy and pharmacology, 2011-04, Vol.67 (4), p.967-969</ispartof><rights>The Author(s) 2011</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-c97aa663420e20725cb6eb972f30a807e380f727d4cd0f42b2e7ed3dc48c690b3</citedby><cites>FETCH-LOGICAL-c475t-c97aa663420e20725cb6eb972f30a807e380f727d4cd0f42b2e7ed3dc48c690b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-011-1582-3$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-011-1582-3$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21327932$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-00671228$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Helbig, Grzegorz</creatorcontrib><creatorcontrib>Moskwa, Andrzej</creatorcontrib><creatorcontrib>Hus, Marek</creatorcontrib><creatorcontrib>Piszcz, Jarosław</creatorcontrib><creatorcontrib>Swiderska, Alina</creatorcontrib><creatorcontrib>Urbanowicz, Alina</creatorcontrib><creatorcontrib>Całbecka, Małgorzata</creatorcontrib><creatorcontrib>Seferyńska, Ilona</creatorcontrib><creatorcontrib>Raźny, Małgorzata</creatorcontrib><creatorcontrib>Rodzaj, Marek</creatorcontrib><creatorcontrib>Żuk, Ewa</creatorcontrib><creatorcontrib>Kyrcz-Krzemień, Sławomira</creatorcontrib><title>Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - pharmacokinetics</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzamides</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Chronic Disease</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Hypereosinophilic Syndrome - drug therapy</subject><subject>Hypereosinophilic Syndrome - pathology</subject><subject>Imatinib Mesylate</subject><subject>Letter to the Editor</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>mRNA Cleavage and Polyadenylation Factors - genetics</subject><subject>Oncogene Proteins, Fusion - genetics</subject><subject>Oncology</subject><subject>Pharmacology/Toxicology</subject><subject>Piperazines - administration & dosage</subject><subject>Piperazines - pharmacokinetics</subject><subject>Piperazines - therapeutic use</subject><subject>Pyrimidines - administration & dosage</subject><subject>Pyrimidines - pharmacokinetics</subject><subject>Pyrimidines - therapeutic use</subject><subject>Receptor, Platelet-Derived Growth Factor alpha - genetics</subject><subject>Remission Induction - methods</subject><subject>Retrospective Studies</subject><subject>Splenomegaly - etiology</subject><subject>Time Factors</subject><subject>Young Adult</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kc9O3DAQxq2KqmyhD9BL5SsHt-M_GycXJAQsIK1UVJWz5TgTYpqNV3Z2ERIvxYv0mepVCqIcerI8833fePwj5DOHrxxAf0sAogQGnDM-LwWT78iMKykYlErukRlIpdhcg9onH1O6AwDFpfxA9gWXQldSzMjj2SbaukcaceVT8mGgth0x0jGiHVc4jPTejx3dYnygfbinTUiYaGipX9nRD76mbYh0cXXNl5xdn10sfvx-YuuQ_Oi3SF0Xw-AdxVwYwrrzfb70uPll8zh7SN63tk_46e95QG4W5z9PL9ny-8XV6cmSOaXnI3OVtrYopBKAArSYu7rAutKilWBL0ChLaLXQjXINtErUAjU2snGqdEUFtTwgx1PuelOvsHF5q2h7s455h_hggvXm387gO3MbtkZCocqqygFHU0D3xnZ5sjS7GkChuRDllmctn7QuhpQiti8GDmaHzUzYTMZmdtiMzJ4vrx_44njmlAViEqTcGm4xmruwiUP-tP-k_gE1K6WA</recordid><startdate>20110401</startdate><enddate>20110401</enddate><creator>Helbig, Grzegorz</creator><creator>Moskwa, Andrzej</creator><creator>Hus, Marek</creator><creator>Piszcz, Jarosław</creator><creator>Swiderska, Alina</creator><creator>Urbanowicz, Alina</creator><creator>Całbecka, Małgorzata</creator><creator>Seferyńska, Ilona</creator><creator>Raźny, Małgorzata</creator><creator>Rodzaj, Marek</creator><creator>Żuk, Ewa</creator><creator>Kyrcz-Krzemień, Sławomira</creator><general>Springer-Verlag</general><general>Springer Verlag</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope></search><sort><creationdate>20110401</creationdate><title>Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia</title><author>Helbig, Grzegorz ; Moskwa, Andrzej ; Hus, Marek ; Piszcz, Jarosław ; Swiderska, Alina ; Urbanowicz, Alina ; Całbecka, Małgorzata ; Seferyńska, Ilona ; Raźny, Małgorzata ; Rodzaj, Marek ; Żuk, Ewa ; Kyrcz-Krzemień, Sławomira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-c97aa663420e20725cb6eb972f30a807e380f727d4cd0f42b2e7ed3dc48c690b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - pharmacokinetics</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzamides</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Chronic Disease</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Hypereosinophilic Syndrome - drug therapy</topic><topic>Hypereosinophilic Syndrome - pathology</topic><topic>Imatinib Mesylate</topic><topic>Letter to the Editor</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>mRNA Cleavage and Polyadenylation Factors - genetics</topic><topic>Oncogene Proteins, Fusion - genetics</topic><topic>Oncology</topic><topic>Pharmacology/Toxicology</topic><topic>Piperazines - administration & dosage</topic><topic>Piperazines - pharmacokinetics</topic><topic>Piperazines - therapeutic use</topic><topic>Pyrimidines - administration & dosage</topic><topic>Pyrimidines - pharmacokinetics</topic><topic>Pyrimidines - therapeutic use</topic><topic>Receptor, Platelet-Derived Growth Factor alpha - genetics</topic><topic>Remission Induction - methods</topic><topic>Retrospective Studies</topic><topic>Splenomegaly - etiology</topic><topic>Time Factors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Helbig, Grzegorz</creatorcontrib><creatorcontrib>Moskwa, Andrzej</creatorcontrib><creatorcontrib>Hus, Marek</creatorcontrib><creatorcontrib>Piszcz, Jarosław</creatorcontrib><creatorcontrib>Swiderska, Alina</creatorcontrib><creatorcontrib>Urbanowicz, Alina</creatorcontrib><creatorcontrib>Całbecka, Małgorzata</creatorcontrib><creatorcontrib>Seferyńska, Ilona</creatorcontrib><creatorcontrib>Raźny, Małgorzata</creatorcontrib><creatorcontrib>Rodzaj, Marek</creatorcontrib><creatorcontrib>Żuk, Ewa</creatorcontrib><creatorcontrib>Kyrcz-Krzemień, Sławomira</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Helbig, Grzegorz</au><au>Moskwa, Andrzej</au><au>Hus, Marek</au><au>Piszcz, Jarosław</au><au>Swiderska, Alina</au><au>Urbanowicz, Alina</au><au>Całbecka, Małgorzata</au><au>Seferyńska, Ilona</au><au>Raźny, Małgorzata</au><au>Rodzaj, Marek</au><au>Żuk, Ewa</au><au>Kyrcz-Krzemień, Sławomira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2011-04-01</date><risdate>2011</risdate><volume>67</volume><issue>4</issue><spage>967</spage><epage>969</epage><pages>967-969</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>21327932</pmid><doi>10.1007/s00280-011-1582-3</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2011-04, Vol.67 (4), p.967-969 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3064899 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Benzamides Cancer Cancer Research Chronic Disease Dose-Response Relationship, Drug Female Follow-Up Studies Humans Hypereosinophilic Syndrome - drug therapy Hypereosinophilic Syndrome - pathology Imatinib Mesylate Letter to the Editor Life Sciences Male Medicine Medicine & Public Health Middle Aged mRNA Cleavage and Polyadenylation Factors - genetics Oncogene Proteins, Fusion - genetics Oncology Pharmacology/Toxicology Piperazines - administration & dosage Piperazines - pharmacokinetics Piperazines - therapeutic use Pyrimidines - administration & dosage Pyrimidines - pharmacokinetics Pyrimidines - therapeutic use Receptor, Platelet-Derived Growth Factor alpha - genetics Remission Induction - methods Retrospective Studies Splenomegaly - etiology Time Factors Young Adult |
| title | Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T05%3A55%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-hal_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Durable%20remission%20after%20treatment%20with%20very%20low%20doses%20of%20imatinib%20for%20FIP1L1-PDGFR%CE%B1-positive%20chronic%20eosinophilic%20leukaemia&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Helbig,%20Grzegorz&rft.date=2011-04-01&rft.volume=67&rft.issue=4&rft.spage=967&rft.epage=969&rft.pages=967-969&rft.issn=0344-5704&rft.eissn=1432-0843&rft_id=info:doi/10.1007/s00280-011-1582-3&rft_dat=%3Chal_pubme%3Eoai_HAL_hal_00671228v1%3C/hal_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/21327932&rfr_iscdi=true |